Pharmaceutical Products Fact Sheet
Abbott focuses on breakthrough science to develop effective treatments and solve unmet medical needs. The company also continues to pursue additional indications for new and existing drugs that offer physicians treatment options. Abbott had worldwide revenues of $14.6 billion in its Pharmaceutical Products business in 2007.
Key Therapeutic Areas/Products
Anesthesia
- Ultane®/Sevorane®
Inhalation anesthetic for both inpatient and outpatient procedures.
Cardiology
- Niaspan®
An extended-release niacin product that raises HDL, or "good" cholesterol levels. - SIMCOR®
A fixed-dose combination of Niaspan and simvastatin that targets both "good" and "bad" cholesterol in a single pill. - TriCor®
Used along with dietary fat restriction to reduce triglycerides and LDL, or "bad" cholesterol, and to increase HDL, or "good" cholesterol.
Immunology
- HUMIRA®
Biologic therapy approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, Crohn's disease and psoriasis.
Infectious Diseases
- Kaletra®/Aluvia®
Protease inhibitor for the treatment of HIV/AIDS.
Metabolic Diseases
- Synthroid®
Synthetic thyroid hormone for the treatment of hypothyroidism.
Neuroscience and Pain
- Depakote® ER
Anti-epileptic agent also used for the treatment of manic episodes of bipolar disorder and for the prevention of migraine headaches.
Renal Care
- Zemplar®
Next-generation therapy for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.
